Myelofibrosis is a rare type of bone marrow cancer. In this condition, extensive scarring (fibrosis) occurs in the bone marrow, which keeps the bone marrow from producing the right number of blood ...

Panelists discuss how myelofibrosis progresses from its molecular and genetic origins through various clinical manifestations ...

Ten days of subcutaneous Dacogen resulted in responses among a third of patients with myelofibrosis. Among patients with ...

Panelists discuss how health care providers can optimize quality-of-life and treatment outcomes for patients with ...

Around 100,000 Australians live with myelofibrosis, which is a rare form of blood cancer. But an Australian-developed drug - ...

and the presence of other characteristic features within the marrow (eg, myelofibrosis in M7) allow us to distinguish among the different subtypes of AML. Modern advances in immunophenotyping ...

Around 100,000 Australians live with a rare form of blood cancer, and a new treatment approved by the medicines watchdog is ...

Myelofibrosis is a type of blood cancer that causes fibrosis in the bone marrow, anemia and enlarged spleen, amongst other symptoms. The study is testing three dose levels of OPN-2853 (20 mg ...

In LR-MDS, abnormal bone marrow cells often express the enzyme ... from any other drug currently approved or in development for myelofibrosis treatment; (ii) that the early results from IMproveMF ...